Navigation Links
Abuse Deterrent Technology Promises Annual Budget Savings Exceeding $200 Billion
Date:3/5/2013

PISGAH FOREST, N.C., March 5, 2013 /PRNewswire/ -- Pisgah Laboratories, Inc. has announced the launch of a new website to assist in its abuse deterrent technology licensing efforts. Over the past several years, Pisgah (www.pisgahlabs.com) has elucidated a technical means to address the Nation's drug abuse epidemic as declared by the Center for Disease Control (CDC). The impact of illicit drug use in America is financially staggering and the statistics are well summarized in a report by the Office of National Drug Control Policy (https://www.ncjrs.gov/ondcppubs/publications/pdf/economic_costs.pdf). Pisgah's patented technology is aimed at introducing abuse deterrent features at the active ingredient level with laboratory results indicating broad applicability to many of the most notoriously abused narcotics and psychotherapeutic medications.

P2P Interventions™, www.P2PINTERVENTIONS.com, is the trademark Pisgah Laboratories has adopted for its platform technology designed to significantly reduce recreational drug abuse of narcotics and psychotherapeutic medications. Pisgah has researched and patented pathways for introducing new narcotic products possessing chemical and physical characteristics, which make recreational drug use not only difficult, but essentially un-economic to the abuser. Unique to Pisgah's approach are that modifications to the salt form selected for the active ingredient impart additional safety features without compromising expected efficacy of the drug. For product manufacturers, additional protective measures can also be added from formulation techniques incorporating the abuse deterrent active ingredient.

As with any pharmaceutical endeavor, the pathway to commercialization is fraught with many challenges and obstacles, but P2P Interventions™ is armed with an essential component for success in today's challenging markets. At its core, P2P Interventions™ is backed by numerous US patents which encompass the technology's groundwork. Additionally, and through Pisgah Labs, new discoveries and improvements on the technology are being routinely submitted to the US Patent & Trademark Office as Pisgah maintains its efforts to fully detail the technical breadth of the inventions. These patents afford potential licensees the opportunity to introduce new pain medications with patent protected revenue streams.

An ongoing applied research program at Pisgah Labs is also complemented by a modern and capable active pharmaceutical ingredient manufacturing facility, which possesses FDA and DEA certifications. This asset is an important factor in implementing P2P Interventions'™ licensing strategy since the technology patents address abuse at the active ingredient level—before formulation and tableting. These latter activities are being performed by a Contract Manufacturing Organization (CMO) intimately familiar with the technology, formulation, and controlled substance processing. Overall, P2P Interventions™ provides a technology portal for a branded marketing group aspiring to participate in new, patent protected products.  As Pisgah's president, Bill Bristol , has stated, "P2P Interventions™ has the provision, and holds the promise of significantly reducing the Nation's drug abuse problem".

In the coming year, P2P Interventions™ will continue its product licensing program while Pisgah Labs advances its proof-of-concept activities into humans.  Results from clinical trial evaluations of its combination hydrocodone / APAP lead product are expected later this year with Bristol commenting that "Pisgah is confident in its technical findings and [that] as a private company, our expenditures on clinical trials would not occur without a high probability of success". Ultimately, the technical underpinnings P2P Interventions™ will share with a licensee include utilizing its technical accomplishments and tangible assets to support a market shift to abuse deterrent drug products. Such a shift away from easy-to-abuse products to pain medications containing abuse deterrent features is estimated to save the Nation over $200 billion per year in expenses associated with drug abuse.

For more information about P2P Interventions™ or Pisgah Laboratories, please contact:

Todd Stamps
803-212-8224

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Pisgah Laboratories
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PCMA: The Drugstore Lobby (Again) Looks to Avoid Fraud and Abuse Detection
2. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
3. Consumer Watchdog Calls For Political Response To Physician Drug Abuse Scandal, Including Mandatory Drug Testing for High Risk Doctors Across California
4. Thousands Of Community Advocates Headed To Capitol Hill Today To Educate Members Of Congress About Substance Abuse Prevention
5. Ameritox Leadership Supports Lawmakers, Pain Practitioners and Patients Confronting Crisis in Pain Medication Abuse
6. Biometrics Limits Abuse while Improving Convenience
7. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
8. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
9. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
10. CLAAD Recognizes The Locking Cap as Top 5 Technology To Reduce Rx Abuse
11. CLAAD Recognizes SMART/Script as Top 5 Technology To Reduce Rx Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)...  A new study by a pair of Geisinger ... therapy to treat chronic pain is not only ineffective, ... consequences, including death. Palliative care physicians ... , M.D., authored the study which provides a review ... study was published in the December 2016 edition of ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... world,s largest abstract and citation database of peer-reviewed literature, providing the ... 5,000 publishers. The new set of metrics will improve decisions on ... adjust a journal,s editorial strategy. ... , CiteScore metrics comprise ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia ... 1, 2017. The name change aligns the entire company with its existing ... care quality. , “We are very proud of the achievements associated with the ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health ... . , Results of the comparative usability study demonstrate that a dictation-based method ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , a ... other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to ... president of sales. , Litsinger joined Mirixa in 2008 after serving as ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):